Ertugliflozin: First Global Approval

Drugs

Volumn 78, Issue 4, 2018, Pages 513-519

  Markham, Anthony ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ERTUGLIFLOZIN; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; STEGLATRO; 5-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-1-HYDROXYMETHYL-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL; ANTIDIABETIC AGENT; FUSED HETEROCYCLIC RINGS; METFORMIN; SITAGLIPTIN;

ACUTE KIDNEY FAILURE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BODY WEIGHT DISORDER; DEHYDRATION; DRUG BIOAVAILABILITY; FAINTNESS; FUNGAL GENITAL INFECTION; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; KETOACIDOSIS; KIDNEY DISEASE; KIDNEY FAILURE; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; POSITIONAL DIZZINESS; PRESYNCOPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; URINARY TRACT INFECTION; VAGINAL PRURITUS; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; METABOLISM; TREATMENT OUTCOME; UNITED STATES;

BLOOD GLUCOSE; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SITAGLIPTIN PHOSPHATE; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85044240071     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-018-0878-6     Document Type: Article

References (25)

1. Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41(2):445–56.
2. Merck & Co Inc. STEGLATRO™ (ertugliflozin) tablets, for oral use: prescribing information. 2017. http://www.merck.com/. Accessed 9 Feb 2018.
3. European Medicines Agency. CHMP summary of opinion: Steglatro (ertugliflozin). 2018. http://www.ema.europa.eu/. Accessed 9 Feb 2018
4. Merck & Co Inc. SEGLUROMET™ (ertugliflozin and metformin hydrochloride) tablets, for oral use: prescribing Information. 2017. http://www.accessdata.fda.gov/. Accessed 9 Feb 2018.
5. Merck & Co Inc. STEGLUJAN™ (ertugliflozin and sitagliptin) tablets, for oral use: prescribing Information. 2017. http://www.accessdata.fda.gov/. Accessed 9 Feb 2018.
6. European Medicines Agency. CHMP summary of opinion: Segluromet (ertugliflozin/metformin). 2018. http://www.ema.europa.eu/. Accessed 9 Feb 2018
7. European Medicines Agency. CHMP summary of opinion: Steglujan (ertugliflozin/sitagliptin). 2018.
8. TM (ertugliflozin and sitagliptin) for adults with type 2 diabetes 2017. http://www.pfizer.com/. Accessed 9 Feb 2018
9. Sahasrabudhe V, Saur D, Matschke K, et al. A phase 1, randomized, placebo- and active-controlled crossover study to determine the effect of single-dose ertugliflozin on QTc interval in healthy volunteers. Clin Pharmacol Drug Dev. 2018. https://doi.org/10.1002/cpdd.421.
10. Sahasrabudhe V, Fediuk DJ, Matschke K, et al. Effect of food on the pharmacokinetics of ertugliflozin and its fixed dose combinations: ertugliflozin/sitagliptin and ertugliflozin/metformin [abstract no. PII-123]. Clin Pharmacol Ther. 2017;101(Suppl 1):S86–7.
11. Sahasrabudhe V, Terra SG, Hickman A, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017;57(11):1432–43.
12. Kumar V, Sahasrabudhe V, Liang Y, et al. Effect of rifampin on the pharmacokinetics of ertugliflozin in healthy subjects [abstract no. PI-063]. Clin Pharmacol Ther. 2016;99(Suppl 1):S47.
13. Sahasrabudhe V, Kumar V, Matschke K, et al. Lack of a clinically meaningful pharmacokinetic interaction between ertugliflozin and glimepiride or simvastatin in healthy subjects [abstract no. PI-061]. Clin Pharmacol Ther. 2016;99(Suppl 1):S46–7.
14. Kumar V, Liang Y, Wei H, et al. Bioequivalence of ertugliflozin/metformin fixed-dose combination tablets and co-administration of respective strengths of individual components [abstract no. PII-071]. Clin Pharmacol Ther. 2017;101(Suppl. 1):S71.
15. Fediuk DJ, Matschke K, Liang Y, et al. Bioequivalence of ertugliflozin/sitagliptin fixed-dose combination tablets and co-administration of respective strengths of individual components. Clin Pharmacol Ther. 2017;101(S1):S63.
16. Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721–8.
17. Frias J, Goldman A, Aronson R, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled type 2 diabetes despite diet and exercise: the 52-week VERTIS MONO study [abstract no. 1208-P]. Diabetes. 2017;66:A322–3.
18. Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13103.
19. Hollander P, Liu J, Hill J, et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther. 2017. https://doi.org/10.1007/s13300-017-0354-4.
20. Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018;9:253–68.
21. Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13116.
22. Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13194.
23. Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2017. https://doi.org/10.1007/s13300-017-0337-5.
24. Amin NB, Wang X, Jain SM, et al. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17(6):591–8.
25. Amin NB, Wang X, Mitchell JR, et al. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17(8):805–8.